Growth Equity Between Venture Capital and Buyout

Sector Definition and Market Structure

Definition and Common Traits

Growth equity provides capital to established, fast-growing companies, typically through minority stakes with little if any leverage at investment. A 2019 Business Law Today article published by the American Bar Association states that there is no universally accepted definition of growth equity, also called growth capital or expansion capital. The article reports that the National Venture Capital Association and its Growth Equity Group describe investors that typically acquire a non-controlling minority interest, investments that are often unlevered or lightly levered, and capital geared toward company expansion or shareholder liquidity.

Cambridge Associates, in its 2013 paper Growth Equity Is All Grown Up, describes the typical target as founder-owned, without prior institutional investment, with a proven business model, organic revenue growth usually in excess of 10 percent and often more than 20 percent, and EBITDA that is positive or expected to be so within 12 to 18 months. The paper states that growth equity often carries negotiated negative control provisions, such as approval of the annual business plan, acquisitions and new debt or equity, and often a right to initiate a liquidity event after typically three to five years.

Position Between Venture Capital and Buyout

Cambridge Associates distinguishes the two neighboring strategies by control, leverage and stage. In a leveraged buyout, debt is expected to be a material contributor to the investment return. Venture capital investors hold similar preferred equity, but because of the nascent stage of most venture-funded companies, the downside protections of growth equity are usually lacking.

Cambridge Associates measured aggregate capital loss ratios on investments made between 1992 and 2008, as of March 31, 2012, of 13 percent for growth equity across 260 investments, 35 percent for venture capital across 22,507 investments, and 15 percent for leveraged buyouts across 5,188 investments. The data are historical and describe the shape of the risk, not current outcomes.

Regulatory Classification

Growth equity is a market convention, and neither section 203 of the Investment Advisers Act nor the SEC rule that defines a venture capital fund uses the term. Under section 203(l), 15 U.S.C. 80b-3(l), an adviser that acts solely for one or more venture capital funds is exempt from registration. SEC Rule 203(l)-1, 17 CFR 275.203(l)-1, limits such a fund to assets other than qualifying investments of no more than 20 percent of its aggregate capital contributions and uncalled committed capital, and to borrowing of no more than 15 percent of that base for a non-renewable term of no longer than 120 calendar days.

The rule counts as a qualifying investment an equity security acquired directly from the portfolio company, so shares bought from existing holders fall into the 20 percent basket. A growth equity strategy that relies on such purchases, or on fund-level borrowing above the 15 percent limit, falls outside the venture capital definition. Its adviser cannot use the venture capital exemption and must register or qualify for another exemption, such as the private fund adviser exemption in section 203(m), 15 U.S.C. 80b-3(m), for advisers solely to private funds with assets under management in the United States of less than $150 million.

Firm Identity

LeverVenture is not Lever VC, Lever Capital Partners, Lever for Change, Lever Foundation or Lever (lever.co, a product of Employ Inc.), and none of them is a parent, subsidiary, affiliate, predecessor or successor of LeverVenture.

Investment Criteria and Underwriting

Stage and Ownership Posture

LeverVenture holds the seat between venture capital and private equity. Our mandate is the passage in which a proven technology becomes a company. We enter at the commercial inflection, when the science is settled enough to be a company, the first real buyers exist, and the next constraint is a commercial one.

Our ownership posture is a minority position sized to matter to us and to the company. We lead or co-lead where the company wants an operator at the table. We do not underwrite unproven science, and we do not take passive positions.

Screening Conditions

Every company must meet all seven conditions of the thesis: market, position, evidence, unit economics, management, exit logic and impact. A company that misses one is a decline with a written reason, never a smaller position. The evidence condition requires technical and, where it applies, clinical risk to be substantially retired, so we underwrite execution risk on purpose. The exit condition requires a written view, formed at entry, of who buys the company.

The LeverRating

Each opportunity is scored on the LeverRating, a house framework of six weighted dimensions: Team, Market, Product, Traction, Financial and Thesis fit. The weights are fixed before a company is scored. For a device, a diagnostic or a therapeutic, Product expands into regulatory position, clinical evidence, reimbursement and freedom to operate, each carrying its own weight, and both rulers are run. After an investment, the same six dimensions are scored again on the reporting cadence.

ROI² and the Impact Measure

ROI², Return on Investment and Impact, underwrites commercial success and positive outcomes together, on the same evidence. The second return is measured across access to care, healthy life extended and system cost removed. One impact measure is named at entry with a baseline, an owner and a reporting cadence, and it reports alongside revenue, gross margin and cash.

Regulatory and Reimbursement Gates

In healthcare, federal law gates revenue before a growth equity profile can form. No new drug may be introduced into interstate commerce unless an approved application is effective, under 21 U.S.C. 355(a), and no biological product may be introduced unless a biologics license is in effect, under 42 U.S.C. 262(a)(1). FDA states that a device subject to premarket notification may not be marketed in the United States until the submitter receives a letter finding it substantially equivalent. Medicare adds a payment gate, because 42 U.S.C. 1395y(a)(1)(A) bars payment under Part A or Part B for items and services that are not reasonable and necessary for the diagnosis or treatment of illness or injury.

Commercial-stage diagnostics, device and digital health companies therefore meet the growth equity profile sooner than clinical-stage therapeutics, which cannot generate product revenue before approval. The strongest candidates rarely sit in a single sector. A medical device that is also deep tech, a care platform that is also a digital business, or a health-outcome company built on clean tech, each with artificial intelligence as the layer that makes it work, is the target, and we underwrite the whole company as a single object.

Artificial Intelligence as the Accelerant

Artificial intelligence is the accelerant across all five sectors of the mandate: Biopharma and Therapeutics, Diagnostics and Precision Medicine, Devices and Robotics, Digital Health and Delivery, and Longevity and Neuro. It is never a sixth sector. It is the layer that compresses the timeline inside each sector, and we underwrite it where it shortens a specific timeline in a specific company. The evidence standard for those claims, measured against the regulatory record, validation and the quality system, is set out in AI Diligence in Life Sciences.

Reference Entries

Metrics

• Multiple on Invested Capitalrealized and unrealized value divided by the capital invested, expressed as a multiple.
• Total Value to Paid-In (TVPI)distributions plus remaining value, divided by the capital limited partners have contributed.
• Distributions to Paid-In Capital (DPI)cumulative distributions divided by paid-in capital, the realization multiple under the Global Investment Performance Standards.
• The J-Curvethe early negative stretch in a fund's net cash flow and reported returns before investments mature.
• The Illiquidity Premiumthe price discount investors require to hold an asset that cannot readily be traded.

Structure

• Carried Interestthe general partner's share of profits after limited partners recover capital and any preferred return.
• Distribution Waterfallthe contractual order of capital, preferred return, catch-up and profit split.
• Capital Calla general partner's request that limited partners transfer pledged capital.
• Co-Investmentan investment made beside a private equity fund's own position in the same transaction.
• Special Purpose Vehicle (SPV)a separate legal entity formed to acquire one investment for its owners.
• Key Person Provisionthe term that suspends an investment period when named individuals step back.

Market

• Growth Equitythe full definition, worked example and regulatory classification.
• Private Equity Secondariesthe sale of existing private fund stakes to a new buyer, LP-led or GP-led.
• Emerging Managerhow institutional programs classify a newly formed or relatively small firm.
• Due Diligence Questionnaire (DDQ)the standardized ILPA template a general partner completes for limited partners.

Related Analysis

• Growth EquityGrowth Equity in Life Sciences: 2026 Market Studythe data, the five sectors in play, and where the mid-market financing gap sits.
• Growth EquityOperator-Led vs. Financial-Sponsor Growth Equity: What an Operating Partner Changes for LPshow the two models differ, and what a limited partner should ask about an operating partner model.
• Growth EquityPrivate Equity Meets the Mid-Market: Borrowing PE's Discipline Without the Buyoutwhat a growth company should borrow from private equity, and why it should refuse control and leverage.

Governing Authority and Sources

• SEC, 17 CFR 275.203(l)-1, Venture capital fund defined (eCFR, current as of October 2026)
• Investment Advisers Act of 1940, section 203(l) and (m), 15 U.S.C. 80b-3
• Cambridge Associates, Growth Equity Is All Grown Up (2013; data as of March 31, 2012)
• American Bar Association, Business Law Today, Growth Private Equity Investment in the Fintech Sector (2019)
• Federal Food, Drug, and Cosmetic Act section 505(a), 21 U.S.C. 355(a)
• Public Health Service Act section 351(a), 42 U.S.C. 262(a)(1)
• FDA, Premarket Notification 510(k)
• Social Security Act section 1862(a)(1)(A), 42 U.S.C. 1395y(a)(1)(A)